Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Hold" by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have received an average rating of "Hold" from the seven research firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.17.

A number of equities analysts recently commented on the company. Stifel Nicolaus cut their price objective on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Barclays lowered their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price objective for the company. Piper Sandler lowered their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Finally, UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th.

Elanco Animal Health Trading Down 2.4 %

Shares of Elanco Animal Health stock traded down $0.26 on Wednesday, hitting $10.56. The stock had a trading volume of 1,101,758 shares, compared to its average volume of 4,766,748. The stock has a 50 day moving average of $11.27 and a 200 day moving average of $12.48. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a twelve month low of $10.03 and a twelve month high of $18.80. The firm has a market capitalization of $5.22 billion, a P/E ratio of 26.36, a PEG ratio of 2.50 and a beta of 1.44.

Remove Ads

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS. Sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.57% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the business. Commerce Bank lifted its stake in Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company's stock valued at $516,000 after acquiring an additional 741 shares during the period. Hillsdale Investment Management Inc. increased its stake in Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock worth $524,000 after buying an additional 900 shares during the period. Arizona State Retirement System boosted its position in Elanco Animal Health by 0.8% during the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock valued at $1,737,000 after acquiring an additional 1,166 shares in the last quarter. MTM Investment Management LLC boosted its holdings in shares of Elanco Animal Health by 9.3% in the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock valued at $172,000 after buying an additional 1,200 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in Elanco Animal Health by 5.9% in the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company's stock worth $388,000 after purchasing an additional 1,464 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.